AI Article Synopsis
- Approximately 5% of patients with non-small cell lung cancer (NSCLC) have gene rearrangements, particularly ALK rearrangements.
- While ALK inhibitors like crizotinib initially lead to significant responses in patients, most experience a relapse within a year due to resistance.
- A case study presented highlights a patient with variant type 2-rearranged lung adenocarcinoma who maintained a complete response to crizotinib for over 5 years, indicating that the variant type may be crucial for determining effective treatment strategies.
Article Abstract
gene rearrangements are identified in approximately 5% of patients with non-small cell lung cancer (NSCLC). Despite initial dramatic responses to ALK inhibitors, the majority of patients relapse within 1 year, owing to the development of resistance. Herein we present a case of variant type 2 -rearranged lung adenocarcinoma recurrence with multiple lung metastasis that maintained complete response over 5 years with crizotinib, which is the first approved ALK inhibitor. The efficacy of crizotinib may vary among ALK fusion variants and thus, variant type may represent an important factor in guiding the treatment strategy for -rearranged lung adenocarcinoma.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667864 | PMC |
| http://dx.doi.org/10.3892/mco.2019.1892 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!